within Pharmacolibrary.Drugs.N_NervousSystem.N02B_OtherAnalgesicsAndAntipyretics.N02BF03_Mirogabalin;
model Mirogabalin_1 
   extends Pharmacolibrary.Drugs.ATC.N.N02BF03_1;

  annotation(Documentation(
    info ="<html><body><p>Mirogabalin is an oral gabapentinoid derivative developed for the treatment of neuropathic pain, including diabetic peripheral neuropathic pain and postherpetic neuralgia. It is a selective ligand for the α2δ subunit of voltage-gated calcium channels. Mirogabalin is approved in Japan and several Asian countries for pain management.</p><h4>Pharmacokinetics</h4><p>Population PK analysis from pooled adult studies, median age 50, mixed sex, various doses (therapeutic range).</p><h4>References</h4><ol><li><p>Yamamura, N, et al., &amp; Vashi, V (2021). Metabolism, excretion, and pharmacokinetics of [. <i>Xenobiotica; the fate of foreign compounds in biological systems</i> 51(5) 549–563. DOI:<a href=&quot;https://doi.org/10.1080/00498254.2021.1879408&quot;>10.1080/00498254.2021.1879408</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/33487061/&quot;>https://pubmed.ncbi.nlm.nih.gov/33487061</a></p></li><li><p>Yamamura, N, et al., &amp; Nishiya, Y (2022). Pharmacokinetics and metabolism of mirogabalin, a novel α. <i>Xenobiotica; the fate of foreign compounds in biological systems</i> 52(1) 54–64. DOI:<a href=&quot;https://doi.org/10.1080/00498254.2022.2049396&quot;>10.1080/00498254.2022.2049396</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/35249464/&quot;>https://pubmed.ncbi.nlm.nih.gov/35249464</a></p></li><li><p>Kato, M, et al., &amp; Ishizuka, H (2018). Pharmacokinetics and Safety of a Single Oral Dose of Mirogabalin in Japanese Subjects With Varying Degrees of Renal Impairment. <i>Journal of clinical pharmacology</i> 58(1) 57–63. DOI:<a href=&quot;https://doi.org/10.1002/jcph.974&quot;>10.1002/jcph.974</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/28834546/&quot;>https://pubmed.ncbi.nlm.nih.gov/28834546</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>",
    experiment(StartTime = 0, StopTime = 86400, Tolerance = 1e-09, Interval = 1)
  ));  
end Mirogabalin_1;
